Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a402ed10eafbad68

Jump to content

// Workers AI · dad joke modeWhat did GenScript say to Biotech? "Gene-ially" happy to meet you.

From Wikipedia, the free encyclopedia
GenScript Biotech Corporation
TypePublic
SEHK: 1548
Industry
Founded2002; 24 years ago (2002) in New Jersey, United States
Founders
  • Frank Zhang
  • Sally Wang
  • Larry Wang
Headquarters
Key peopleSherry Shao, (rotating CEO)
Revenue$959.5 million[1] (2025)
Number of employees
6,165[1] (2025)
Subsidiaries
  • GenScript Life Science Group
  • ProBio
  • Bestzyme
Websitewww.genscript.com Edit this at Wikidata

GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a Chinese biotech company. It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang.[2][3] Headquartered in Nanjing,[4] the company provides equipment and services for the life sciences.[5] It was listed on the Hong Kong Stock Exchange in 2015.[6] The current rotating CEO of the firm is Sherry Shao, who previously served as the chief operating officer and Chinese Communist Party Committee Secretary for the company.[7][8] The company's subsidiaries include GenScript Life Science Group, ProBio Technology, and Bestzyme.[9][10][11]

History

[edit]

GenScript Biotech Corporation was founded in 2002 in New Jersey by Fangliang "Frank" Zhang,[12] Ye "Sally" Wang,[13] and Luquan "Larry" Wang.[7] In 2004, it set up a research and production base in Nanjing, China, where it is now headquartered.[14][9] It operates in the United States, China, and Singapore.[15]

In 2013, it established its subsidiary Bestzyme.[14] In the following year, another subsidiary, Legend Biotech, was founded.[16] In 2015, GenScript went public on the Hong Kong Stock Exchange.[14]

In 2017, the Chinese government accepted Nanjing Legend's application for running clinical trials for its blood cancer treatment.[17]

In 2020, its subsidiary Probio was launched[18] and Legend Biotech was listed on the NASDAQ.[19] In the same year, Genscript collaborated with Duke-NUS Medical School to develop and manufacture a serology test called cPass for the detection of COVID-19.[20] On November 6, the cPass test received emergency use authorization from the US FDA.[21][22]

In 2022, Carvykti, a CAR-T cell therapy developed by Janssen Biotech and Legend Biotech,[18] was approved by the US FDA for the treatment of multiple myeloma in adult patients.[23]

Security concerns

[edit]

In May 2024, the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party asked the Federal Bureau of Investigation (FBI) and Director of National Intelligence for a briefing on whether the Chinese government has any undue influence over GenScript and three of its subsidiaries (Bestzyme, Legend Biotech, and ProBio).[24][25]

References

[edit]
  1. 1 2 "Annual Results Announcement For The Year Ended December 31, 2025" (PDF). GenScript. Retrieved 14 April 2026.
  2. Weijing Zhou. "KPCB invests $15 mln in Jinsite". 21st Century Business Herald. June 20, 2009.{{cite web}}: CS1 maint: deprecated archival service (link)
  3. Venus Feng and Yoojung Lee (May 31, 2018). "Road to Chinese Pharma Riches Runs Through the Bronx, New Jersey". Bloomberg News.{{cite web}}: CS1 maint: deprecated archival service (link)
  4. "Genscript Biotech Corp Company Profile - Genscript Biotech Corp Overview". www.globaldata.com. Archived from the original on 2025-12-06. Retrieved 2026-05-24.
  5. Yuexiang Zhou (May 10, 2023). "Singapore Strives to Become Asia's Biomedical Hub". Lianhe Zaobao.{{cite web}}: CS1 maint: deprecated archival service (link)
  6. Eric Ng (December 22, 2017). "Genscript's shares jump by a third on US$350m Johnson & Johnson unit tie-up". South China Morning Post.{{cite web}}: CS1 maint: deprecated archival service (link)
  7. 1 2 "RESIGNATION OF ROTATING CHIEF EXECUTIVE OFFICER" (PDF). hkexnews.hk. GenScript. Retrieved 8 January 2026.
  8. "我院党委与金斯瑞集团党委举行党建共建暨校企合作签约仪式" [The Party Committee of our college and the Party Committee of GenScript Group held a signing ceremony for joint party building and school-enterprise cooperation]. Nanjing University (in Chinese). 2022-06-30. Archived from the original on June 30, 2022. Retrieved 2024-06-02.
  9. 1 2 Keenan, Joseph (2 November 2021). "GenScript embraces automation at its first cell, gene therapy manufacturing US site". Fierce Pharma. Retrieved 8 January 2026.
  10. Keenan, Joseph (26 June 2024). "Genscript's ProBio CDMO arm debuts new gene therapy production plant". Fierce Pharma. Retrieved 8 January 2026.
  11. "Annual Results Announcement For The Year Ended December 31, 2024" (PDF). hkexnews.hk. GenScript. Retrieved 8 January 2026.
  12. Feng, Venus; Lee, Yoojung (31 May 2018). "Road to China Drug Riches Runs Through the Bronx, New Jersey". Bloomberg News. Retrieved 8 January 2026.
  13. Chen, I-Chun (9 November 2020). "Legend Biotech names Huang permanent CEO, Wang chairwoman". New York Business Journal. Retrieved 8 January 2026.
  14. 1 2 3 "Handbook of GenScript Biotech (2022 Edition)" (PDF). www.genscript.com. May 24, 2022. Archived (PDF) from the original on December 6, 2022.
  15. "GenScript Launches A Protein Manufacturing Facility In Singapore". Lianhe Zaobao. Economic Development Board. January 10, 2023. Archived from the original on 2023-07-13.
  16. Preetika Rana (August 5, 2018). "How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs". The Wall Street Journal.{{cite web}}: CS1 maint: deprecated archival service (link)
  17. Wei, Jianshu; Guo, Yelei; Wang, Yao; Wu, Zhiqiang; Bo, Jian; Zhang, Bin; Zhu, Jun; Han, Weidong (April 2021). "Clinical development of CAR T cell therapy in China: 2020 update". Cellular & Molecular Immunology. 18 (4): 792–804. doi:10.1038/s41423-020-00555-x. PMC 8115146. PMID 32999455.
  18. 1 2 Dede Williams (January 25, 2023). "GenScript Raises $224 Million in Fresh Capital". CHEManager. Archived from the original on June 10, 2023.
  19. Lucinda Shen (June 5, 2020). "ZoomInfo raises nearly $1 billion in its IPO". Fortune.{{cite web}}: CS1 maint: deprecated archival service (link)
  20. Lovelyn Tagalag (May 15, 2020). "GenScript to collaborate with Singapore agency on COVID-19 test". S&P Global.{{cite web}}: CS1 maint: deprecated archival service (link)
  21. "Coronavirus (COVID-19) Update: FDA Authorizes First Test that Detects Neutralizing Antibodies from Recent or Prior SARS-CoV-2 Infection". www.fda.gov. Food and Drug Administration. November 6, 2020. Archived from the original on November 6, 2020.
  22. Tan, Chee-Wah; Chia, Wan-Ni; Young, Barnaby E.; Zhu, Feng; Lim, Beng-Lee; Sia, Wan-Rong; Thein, Tun-Linn; Chen, Mark I.-C.; Leo, Yee-Sin; Lye, David C.; Wang, Lin-Fa (7 October 2021). "Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors". New England Journal of Medicine. 385 (15): 1401–1406. doi:10.1056/NEJMoa2108453. PMC 8422514. PMID 34407341.
  23. Peter Loftus (February 28, 2022). "FDA Approves Cell-Based Multiple Myeloma Therapy Discovered in China". The Wall Street Journal.{{cite web}}: CS1 maint: deprecated archival service (link)
  24. Freifeld, Karen (May 31, 2024). "US lawmakers ask FBI for briefing on GenScript Biotech's links to China". Reuters. Retrieved May 31, 2024.
  25. "Moolenaar, Krishnamoorthi Request FBI & DNI Briefing on Chinese Communist Party-Linked Biotech Firm". Select Committee on the CCP. 2024-05-31. Archived from the original on 2024-06-02. Retrieved 2024-06-02.
[edit]